Fish oil boosts cancer immunotherapy? new trial investigates
NCT ID NCT07272382
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase II trial is testing whether adding omega-3 fatty acid supplements to standard immunotherapy (PD-1 inhibitors) can help patients with advanced esophageal cancer. About 142 adults will be randomly assigned to receive either omega-3 or placebo drops daily for six months, alongside their cancer treatment. The main goal is to see if omega-3 helps maintain muscle mass, with additional checks on treatment response and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Omega-3 fatty acids (EPA and DHA)
What this could lead to
If it works, this could show that adding omega-3 supplements to standard immunotherapy helps patients maintain muscle mass and possibly improve treatment outcomes.
What could go wrong
This is a small, early-phase trial with 142 participants, so results may not apply to everyone. Omega-3 might not provide any benefit over placebo, and side effects from the supplements are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.